Big Pharma backers jump on board 'Treg' cartographer's lead round with up to six candidates in the pipe

Among the wealth of emerging targets in oncology, immune system suppressing regulatory T cells — better known as “Tregs” — have earned some big-name interest in recent years. Now, a West Coast startup mapping Tregs in human tissue has scored a slate of Big Pharma backers to drive its growing pipeline into the clinic.